July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Will potential study participants choose a vaccine trial over getting access to PrEP?
Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.
Racism and Homophobia in Health Care Settings May Reduce PrEP Uptake for Young Black Gay and Bisexual Men, Study Finds
Racial segregation and medical mistrust in Milwaukee may keep pre-exposure prophylaxis out of their hands.
June 20, 2019: Housing stability and HIV viremia; how the stigma of poverty affects viral load; the best time to employ syringe services; promise for the practice of index testing.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Black men who have sex with men test in high numbers over a lifetime, but not frequently or recently.
The US Preventive Services Task Force released its final ruling in *JAMA*.
"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.